ODI Pharma AB (publ) reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported revenue was SEK 2.95 million compared to SEK 0.080524 million a year ago. Net income was SEK 0.946531 million compared to net loss of SEK 1.735 million a year ago. Basic earnings per share from continuing operations was SEK 0.06 compared to basic loss per share from continuing operations of SEK 0.09 a year ago.
For the six months, revenue was SEK 3.74 million compared to SEK 0.126386 million a year ago. Net loss was SEK 0.491858 million compared to SEK 3.424 million a year ago. Basic loss per share from continuing operations was SEK 0.03 compared to SEK 0.17 a year ago.